Annovis Bio, Inc. (ANVS)
| Market Cap | 48.57M +7.9% |
| Revenue (ttm) | n/a |
| Net Income | -49.52M |
| EPS | -1.79 |
| Shares Out | 42.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,201,835 |
| Open | 1.100 |
| Previous Close | 1.120 |
| Day's Range | 1.095 - 1.170 |
| 52-Week Range | 1.095 - 5.500 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+821.05%) |
| Earnings Date | Aug 14, 2026 |
About ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price target is $10.5, which is an increase of 821.05% from the latest price.
News
Annovis Bio Proxy statement: Proxy filing
Annovis Bio filed a proxy statement on September 11, 2026, providing details for shareholder voting and corporate governance matters.
Annovis Bio Transcript: Investor update
Pivotal phase III Alzheimer's trial is fully enrolled, with top-line data expected in March and NDA filing to follow. Additional funding is required to continue operations, with management and insiders planning to participate in the raise. Disease-modifying data in 2028 could unlock significant market opportunities.
Annovis Bio price target lowered to $7 from $8 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappa lowered the firm’s price target on Annovis Bio (ANVS) to $7 from $8 and keeps a Buy rating on the shares. Pressure is disproportionately building…
Annovis to Host Corporate Update Webinar on September 2, 2026
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis Bio Proxy statement: Proxy filing
Annovis Bio filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis Bio Earnings release: Q2 2026
Annovis Bio released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Annovis Bio Quarterly report: Q2 2026
Annovis Bio has published its Q2 2026 quarterly earnings report on August 14, 2026.
Annovis Bio Slides: Investor presentation
Annovis Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Annovis Bio initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Annovis Bio (ANVS) with a Buy rating and $8 price target The firm is bullish on the company’s Alzheimer’s disease program based on Buntanetap’s safety…
Annovis Bio announces full enrollment for buntanetap trial
Annovis Bio (ANVS) announced full enrollment of its pivotal Phase 3 trial evaluating buntanetap in patients with early AD. The trial enrolled 850 patients with pTau217-confirmed AD pathology across 83...
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for...
Annovis Bio promotes Cheng Fang to chief scientific officer
Annovis Bio (ANVS) announced the promotion of Cheng Fang to chief scientific officer. Fang, who joined Annovis in 2021 and most recently served as senior VP, research and development, will…
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,...
Annovis Bio regains NYSE listing compliance
Annovis Bio (ANVS) announced that it has regained compliance with the New York Stock Exchange, NYSE, continued listing standards. “We are pleased to have regained full NYSE compliance in just…
Annovis Bio Regains NYSE Listing Compliance
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, ...
Annovis Bio 7.9M share Spot Secondary priced at $1.90
The deal priced below last closing price of $1.94. Canaccord is acting as sole book running manager for the offering.
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, ...
Annovis Bio announces common stock and warrants offering, no amount given
Annovis Bio (ANVS) announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares…
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, ...
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026 New D...
Annovis Bio Quarterly report: Q1 2026
Annovis Bio has published its Q1 2026 quarterly earnings report on May 15, 2026.
Annovis Bio Earnings release: Q1 2026
Annovis Bio released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Annovis Bio Slides: Corporate presentation
Annovis Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, ...